Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Fernvik E, Sierra Madero J, Espinosa N, Gulminetti R, Hagins D, Tsai HC, Man C, Sievers J, Grove R, Zolopa A, Wynne B, van Wyk J, Ait-Khaled M. Fernvik E, et al. Among authors: van wyk j. J Acquir Immune Defic Syndr. 2023 Nov 1;94(3):e9-e12. doi: 10.1097/QAI.0000000000003280. J Acquir Immune Defic Syndr. 2023. PMID: 37850985 No abstract available.
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide-Based Regimens.
Batterham RL, Espinosa N, Katlama C, McKellar M, Scholten S, Smith DE, Ait-Khaled M, George N, Wright J, Gordon LA, Moodley R, Wynne B, van Wyk J. Batterham RL, et al. Among authors: van wyk j. Open Forum Infect Dis. 2023 Jul 12;10(7):ofad359. doi: 10.1093/ofid/ofad359. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37520420 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 38134313
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y, Han K, Van Eygen V, Crauwels H, Ford SL, Latham CL, St Clair M, Polli JW, Vanveggel S, Vandermeulen K, D'Amico R, Garges HP, Zolopa A, Spreen WR, van Wyk J, Cutrell AG. Orkin C, et al. Among authors: van eygen v, van wyk j. Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370. Clin Infect Dis. 2023. PMID: 37340869 Free PMC article.
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.
Teichner P, Chamay N, Elliot E, Pascual-Bernáldez M, Merrill D, Garris C, D'Amico R, Felizarta C, Torres E, Van Solingen-Ristea R, Baugh B, Patel P, Vannappagari V, Dakhia S, Polli JW, Garside L, Grove R, Thiagarajah S, Birmingham E, van Wyk J. Teichner P, et al. Among authors: van solingen ristea r, van wyk j. Open Forum Infect Dis. 2024 May 25;11(6):ofae282. doi: 10.1093/ofid/ofae282. eCollection 2024 Jun. Open Forum Infect Dis. 2024. PMID: 38882931 Free PMC article. Clinical Trial.
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.
Mussini C, Cazanave C, Adachi E, Eu B, Alonso MM, Crofoot G, Chounta V, Kolobova I, Sutton K, Sutherland-Phillips D, Urbaityte R, Ehmann A, Scherzer J, de Los Rios P, D'Amico R, Spreen W, van Wyk J. Mussini C, et al. Among authors: van wyk j. AIDS Behav. 2024 Oct 8. doi: 10.1007/s10461-024-04490-0. Online ahead of print. AIDS Behav. 2024. PMID: 39375290
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Among authors: van solingen ristea r, van eygen v, van wyk j. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Oka S, Holohan V, Shirasaka T, Choi JY, Kim YS, Chamay N, Patel P, Polli JW, Ford SL, Crauwels H, Garside L, D'Amico R, Latham C, van Solingen-Ristea R, Baugh B, van Wyk J. Oka S, et al. Among authors: van solingen ristea r, van wyk j. HIV Med. 2024 Mar;25(3):381-390. doi: 10.1111/hiv.13588. Epub 2023 Dec 26. HIV Med. 2024. PMID: 38147871
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P, Teichner P, Elliot E, Boffito M, Murray M, Polli JW, Baker M, Ford SL, Han K, Russu A, Crauwels H, D'Amico RD, Spreen WR, van Wyk J. Patel P, et al. Among authors: van wyk j. Ther Adv Infect Dis. 2023 Dec 13;10:20499361231214626. doi: 10.1177/20499361231214626. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 38107552 Free PMC article. Review.
554 results